Michael Weichenthal
19PUBLICATIONS
107CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (19)
Sort by Publication Date:
|Mar 15, 2026
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study.Ralf Gutzmer, Michael Weichenthal, Thomas Eigentler
|Feb 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.Michael Weichenthal, Dirk Debus, Lisa Zimmer
|Nov 09, 2024
Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe.Michael Weichenthal, Joanna Mangana, Iva Gavrilova
|Sep 28, 2023
COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma.Carola Berking, Elisabeth Livingstone, Dirk Debus
|Sep 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG.Maximilian Haist, Henner Stege, Friederike Rogall
|Apr 07, 2023
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.Cindy Franklin, Peter Mohr, Leonie Bluhm
Pageof 4
Frequent Collaborators
10 joint publications
Selma Ugurel
7 joint publications
Dirk Schadendorf
6 joint publications
Christoffer Gebhardt
6 joint publications
Ralf Gutzmer
5 joint publications
Jessica C Hassel
5 joint publications
Markus V Heppt
5 joint publications
Jochen Utikal
4 joint publications
Patrick Terheyden
4 joint publications
Sebastian Haferkampf
4 joint publications
Ulrike Leiter
